Nurix Therapeutics Files 8-K Disclosure Update

Ticker: NRIX · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1549595

Sentiment: neutral

Topics: disclosure, sec-filing

Related Tickers: NRIX

TL;DR

Nurix filed a routine 8-K, no major news.

AI Summary

Nurix Therapeutics, Inc. filed an 8-K on September 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events, but serves as a standard disclosure update.

Why It Matters

This filing indicates Nurix Therapeutics is providing standard updates to the SEC, which is routine for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard disclosure and does not report any new material events, financial results, or significant changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Nurix Therapeutics?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant is Nurix Therapeutics, Inc.

In which state was Nurix Therapeutics, Inc. incorporated or organized?

Nurix Therapeutics, Inc. was incorporated or organized in Delaware.

What is the Commission File Number for Nurix Therapeutics, Inc.?

The Commission File Number for Nurix Therapeutics, Inc. is 001-39398.

What is the business address of Nurix Therapeutics, Inc.?

The business address of Nurix Therapeutics, Inc. is 1700 Owens Street, Suite 205, San Francisco, California 94158.

Filing Stats: 622 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-09-05 07:01:49

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Nurix Therapeutics, Inc. (the "Company") intends to conduct meetings with securities analysts, investors and others beginning on September 5, 2024. As part of these meetings, the Company intends to utilize an investor presentation (the "Investor Presentation") which includes updates about the Company's Phase 1 clinical trial evaluating NX-5948 for the treatment of various B-cell malignancies. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith and this list is intended to constitute the exhibit index: Exhibit No. Exhibit Title or Description 99.1 Nurix Therapeutics, Inc. Investor Presentation dated September 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: September 5, 2024 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing